• Shevon S Fernando, Emma K Paige, Claire Dendle, Robert Weinkove, KongDavid C MDCMPharmacy Department, Ballarat Health Service, Ballarat, Victoria, Australia.Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.National Centre for Antimicrobial Stewardship, The Peter Doherty Ins, Paul Omond, David J Routledge, Jeff Szer, Christopher C Blyth, and Australasian Antifungal Guidelines Steering Committee.
• Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia.
• Intern Med J. 2021 Nov 1; 51 Suppl 7: 220-233.

AbstractPatients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential. Sharing information and addressing knowledge gaps are required to ensure those at risk of IFD avoid infection, while those with suspected or confirmed infection optimise their therapy and avoid toxicities. This new addition to the Australian and New Zealand consensus guidelines for the management of IFD and antifungal use in the haematology/oncology setting outlines the key information needs of patients and their carers/families. It specifically addresses risk factor reduction, antifungal agents and adherence, and the risks and benefits of complementary and alternative therapies. Knowledge gaps are also identified to help inform the future research agenda.© 2021 Royal Australasian College of Physicians.

12 keywords...

hide…